The Stamford Hospital
- Type
- Teaching hospital
- Where
- STAMFORD, CT
- Medicare CCN
- 070006
- Received
- $650,066 in 74 records, 2024 ($53,756 general, $596,309 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STAMFORD HOSPITAL Fuzzy (name and state)
- Plan sponsor: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Federal award recipient: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Lobbying client: STAMFORD HOSPITAL Fuzzy (name and state)
- Nonprofit: STAMFORD HOSPITAL Fuzzy (name and state)
- Trademark owner: The Stamford Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 28 | $53,756 |
| 2024 | Research payment | 46 | $596,309 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 17 | $347,911 | 2024 |
| Novartis Pharmaceuticals Corporation | 2 | $97,484 | 2024 |
| E.R. Squibb & Sons, L.L.C. | 4 | $73,419 | 2024 |
| Sumitomo Pharma America, Inc. | 14 | $63,549 | 2024 |
| Siemens Medical Solutions USA, Inc. | 1 | $17,283 | 2024 |
| Stryker Corporation | 4 | $16,712 | 2024 |
| Insulet Corporation | 11 | $9,925 | 2024 |
| Genentech, Inc. | 5 | $7,971 | 2024 |
| Celgene Corporation | 3 | $5,895 | 2024 |
| AstraZeneca Pharmaceuticals LP | 1 | $3,000 | 2024 |
| ABBVIE INC. | 1 | $2,987 | 2024 |
| Tandem Diabetes Care, Inc. | 7 | $2,250 | 2024 |
| bioMerieux Inc | 1 | $586 | 2024 |
| Haemonetics Corporation | 1 | $500 | 2024 |
| CSL Behring | 1 | $500 | 2024 |
| Eli Lilly and Company | 1 | $91 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 46 | $596,309 |
| Grant | 2 | $20,283 |
| Debt forgiveness | 4 | $17,163 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 18 | $12,175 |
| Space rental or facility fees (teaching hospital only) | 2 | $3,500 |
| Education | 1 | $500 |
| Long term medical supply or device loan | 1 | $135 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Stryker Corporation | $16,231 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | PFIZER INC. | $9,845 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-12-31 | Stryker Corporation | $174 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $171 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $135 | Long term medical supply or device loan | In-kind items and services | SPY Device, ENDOSCOPY | 2024 | |
| 2024-12-19 | PFIZER INC. | $20,305 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-12-13 | E.R. Squibb & Sons, L.L.C. | $981 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Study - Breast Cancer HR Pos / HER2 Neg Neo adjuvant | 2024 |
| 2024-12-12 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-12-05 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-26 | PFIZER INC. | $12,550 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-11-20 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-11-06 | Sumitomo Pharma America, Inc. | $17,877 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-11-06 | Novartis Pharmaceuticals Corporation | $2,799 | Research payment | In-kind items and services | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety an | 2024 | |
| 2024-11-06 | Celgene Corporation | $2,000 | Research payment | Cash or cash equivalent | Celgene Connect Myeloid Disease Registry | 2024 | |
| 2024-11-06 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-10-24 | Haemonetics Corporation | $500 | Education | Cash or cash equivalent | TEG6S HEMOSTASIS SYSTEM Device, DEVICES | 2024 | |
| 2024-10-21 | CSL Behring | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-10-17 | Genentech, Inc. | $1,635 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2024 | |
| 2024-10-16 | Insulet Corporation | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-10-09 | PFIZER INC. | $11,082 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-10-03 | ABBVIE INC. | $2,987 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Part | 2024 |
| 2024-10-02 | Insulet Corporation | $375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-30 | bioMerieux Inc | $586 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-09-28 | PFIZER INC. | $12,921 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-09-25 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-20 | Insulet Corporation | $550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-09-11 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-05 | E.R. Squibb & Sons, L.L.C. | $1,895 | Research payment | Cash or cash equivalent | Connect MM The Multiple Myeloma Disease Registry | 2024 | |
| 2024-08-20 | Genentech, Inc. | $985 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2024 | |
| 2024-08-15 | E.R. Squibb & Sons, L.L.C. | $3,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-08-13 | E.R. Squibb & Sons, L.L.C. | $67,543 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibr | 2024 | |
| 2024-07-31 | Sumitomo Pharma America, Inc. | $15,883 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-07-31 | Sumitomo Pharma America, Inc. | $410 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-07-31 | Sumitomo Pharma America, Inc. | $410 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-07-31 | Sumitomo Pharma America, Inc. | $410 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-07-31 | Sumitomo Pharma America, Inc. | $410 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-07-31 | Sumitomo Pharma America, Inc. | $410 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-07-26 | Insulet Corporation | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-06-26 | PFIZER INC. | $21,442 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-06-08 | PFIZER INC. | $27,104 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-06-06 | Genentech, Inc. | $1,709 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2024 | |
| 2024-05-29 | Sumitomo Pharma America, Inc. | $7,105 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-05-29 | Tandem Diabetes Care, Inc. | $175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-05-22 | Insulet Corporation | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-05-22 | Tandem Diabetes Care, Inc. | $175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-05-21 | PFIZER INC. | $44,020 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-05-16 | Celgene Corporation | $1,895 | Research payment | Cash or cash equivalent | Connect MM- The Multiple Myeloma Disease Registry | 2024 | |
| 2024-05-16 | Insulet Corporation | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-05-02 | PFIZER INC. | $30,709 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-04-17 | PFIZER INC. | $13,353 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-04-10 | PFIZER INC. | $28,102 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-04-10 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-04-08 | AstraZeneca Pharmaceuticals LP | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENHERTU Biological, Oncology | 2024 | |
| 2024-04-03 | PFIZER INC. | $13,249 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-04-02 | Insulet Corporation | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-03-29 | PFIZER INC. | $31,619 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-03-28 | PFIZER INC. | $21,302 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-03-19 | Siemens Medical Solutions USA, Inc. | $17,283 | Grant | In-kind items and services | 2024 | ||
| 2024-03-12 | Genentech, Inc. | $808 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2024 | |
| 2024-03-08 | Eli Lilly and Company | $91 | Research payment | In-kind items and services | A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS V | 2024 | |
| 2024-03-02 | PFIZER INC. | $33,636 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-02-21 | Sumitomo Pharma America, Inc. | $10,215 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-02-21 | Sumitomo Pharma America, Inc. | $8,874 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-02-21 | Sumitomo Pharma America, Inc. | $1,432 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-02-21 | Sumitomo Pharma America, Inc. | $80 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-02-21 | Sumitomo Pharma America, Inc. | $15 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-02-21 | Sumitomo Pharma America, Inc. | $15 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-02-08 | Genentech, Inc. | $2,834 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2024 | |
| 2024-02-08 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-02-05 | Insulet Corporation | $1,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2024 | |
| 2024-01-31 | Celgene Corporation | $2,000 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and treatment | 2024 |
| 2024-01-25 | Novartis Pharmaceuticals Corporation | $94,685 | Research payment | Cash or cash equivalent | SCEMBLIX Drug, Oncology | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase | 2024 |
| 2024-01-25 | PFIZER INC. | $1,105 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 | |
| 2024-01-09 | PFIZER INC. | $15,558 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IM | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Stamford, CT, county Western Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) Stamford, CT | County Western Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 137,144 | 627,071 | 3,624,508 |
| Population, 2020 census P1 | 135,470 | - | 3,605,944 |
| Median age B01002 | 38.4 | 41.5 | 41.1 |
| Under 18 B01001 | 18.4% | 21.8% | 20.2% |
| 65 and over B01001 | 16.2% | 17.4% | 18.5% |
| Households B11001 | 55,291 | 235,379 | 1,434,007 |
| Foreign born B05002 | 31.3% | 23.8% | 15.7% |
| Median household income B19013 | $111,586 | $128,188 | $95,781 |
| Median family income B19113 | $126,493 | $161,625 | $122,706 |
| Per capita income B19301 | $67,068 | $82,266 | $55,915 |
| Poverty rate B17001 | 10.1% | 7.5% | 10.0% |
| Unemployment rate B23025 | 4.9% | 5.3% | 5.6% |
| Civilian labor force B23025 | 81,944 | 346,557 | 1,959,490 |
| Mean commute (minutes) B08013 | 28.5 | 30.8 | 26.5 |
| Bachelor's degree or higher B15003 | 51.7% | 55.5% | 42.5% |
| Housing units B25001 | 58,655 | 251,530 | 1,541,822 |
| Owner-occupied B25003 | 48.8% | 66.4% | 66.5% |
| Renters B25003 | 51.2% | 33.6% | 33.5% |
| Median home value B25077 | $624,400 | $652,900 | $366,900 |
| Median gross rent B25064 | $2,276 | $2,110 | $1,488 |
| White, not Hispanic B03002 | 43.2% | 58.6% | 61.9% |
| Black B03002 | 17.7% | 9.3% | 9.8% |
| Hispanic or Latino B03002 | 28.3% | 20.5% | 18.3% |
| Asian B03002 | 7.3% | 5.4% | 4.7% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Stamford, CT.
Comments